These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
141 related articles for article (PubMed ID: 36417840)
1. Prognostic Factors across Poorly Differentiated Neuroendocrine Neoplasms: A Pooled Analysis. Centonze G; Maisonneuve P; Prinzi N; Pusceddu S; Albarello L; Pisa E; Barberis M; Vanoli A; Spaggiari P; Bossi P; Cattaneo L; Sabella G; Solcia E; La Rosa S; Grillo F; Tagliabue G; Scarpa A; Papotti M; Volante M; Mangogna A; Del Gobbo A; Ferrero S; Rolli L; Roca E; Bercich L; Benvenuti M; Messerini L; Inzani F; Pruneri G; Busico A; Perrone F; Tamborini E; Pellegrinelli A; Kankava K; Berruti A; Pastorino U; Fazio N; Sessa F; Capella C; Rindi G; Milione M Neuroendocrinology; 2023; 113(4):457-469. PubMed ID: 36417840 [TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE). Nuñez-Valdovinos B; Carmona-Bayonas A; Jimenez-Fonseca P; Capdevila J; Castaño-Pascual Á; Benavent M; Pi Barrio JJ; Teule A; Alonso V; Custodio A; Marazuela M; Segura Á; Beguiristain A; Llanos M; Martinez Del Prado MP; Diaz-Perez JA; Castellano D; Sevilla I; Lopez C; Alonso T; Garcia-Carbonero R Oncologist; 2018 Apr; 23(4):422-432. PubMed ID: 29330208 [TBL] [Abstract][Full Text] [Related]
3. Gastric neuroendocrine carcinoma: clinicopathologic review and immunohistochemical study of E-cadherin and Ki-67 as prognostic markers. Boo YJ; Park SS; Kim JH; Mok YJ; Kim SJ; Kim CS J Surg Oncol; 2007 Feb; 95(2):110-7. PubMed ID: 17066436 [TBL] [Abstract][Full Text] [Related]
4. The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories. Milione M; Maisonneuve P; Spada F; Pellegrinelli A; Spaggiari P; Albarello L; Pisa E; Barberis M; Vanoli A; Buzzoni R; Pusceddu S; Concas L; Sessa F; Solcia E; Capella C; Fazio N; La Rosa S Neuroendocrinology; 2017; 104(1):85-93. PubMed ID: 26943788 [TBL] [Abstract][Full Text] [Related]
5. A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Elvebakken H; Perren A; Scoazec JY; Tang LH; Federspiel B; Klimstra DS; Vestermark LW; Ali AS; Zlobec I; Myklebust TÅ; Hjortland GO; Langer SW; Gronbaek H; Knigge U; Tiensuu Janson E; Sorbye H Neuroendocrinology; 2021; 111(9):883-894. PubMed ID: 33002892 [TBL] [Abstract][Full Text] [Related]
6. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin. Busico A; Maisonneuve P; Prinzi N; Pusceddu S; Centonze G; Garzone G; Pellegrinelli A; Giacomelli L; Mangogna A; Paolino C; Belfiore A; Kankava K; Perrone F; Tamborini E; Pruneri G; Fazio N; Milione M Neuroendocrinology; 2020; 110(7-8):616-629. PubMed ID: 31557757 [TBL] [Abstract][Full Text] [Related]
7. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas. Tang LH; Basturk O; Sue JJ; Klimstra DS Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015 [TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. Crippa S; Partelli S; Bassi C; Berardi R; Capelli P; Scarpa A; Zamboni G; Falconi M Surgery; 2016 Mar; 159(3):862-71. PubMed ID: 26602841 [TBL] [Abstract][Full Text] [Related]
9. Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms. Shi H; Chen L; Zhang Q; Lin Y; Jiang C; Yao H; Hou X; Chen M; Lin R; Chen J Pancreas; 2020; 49(10):1378-1382. PubMed ID: 33122528 [TBL] [Abstract][Full Text] [Related]
10. Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. Crippa S; Partelli S; Belfiori G; Palucci M; Muffatti F; Adamenko O; Cardinali L; Doglioni C; Zamboni G; Falconi M World J Gastroenterol; 2016 Dec; 22(45):9944-9953. PubMed ID: 28018101 [TBL] [Abstract][Full Text] [Related]
11. Clinicopathological features and prognostic factors associated with gastroenteropancreatic mixed neuroendocrine non-neuroendocrine neoplasms in Chinese patients. Huang YC; Yang NN; Chen HC; Huang YL; Yan WT; Yang RX; Li N; Zhang S; Yang PP; Feng ZZ World J Gastroenterol; 2021 Feb; 27(7):624-640. PubMed ID: 33642833 [TBL] [Abstract][Full Text] [Related]
12. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors. Pelosi G; Bianchi F; Dama E; Metovic J; Barella M; Sonzogni A; Albini A; Papotti M; Gong Y; Vijayvergia N Endocr Pathol; 2021 Sep; 32(3):396-407. PubMed ID: 33433886 [TBL] [Abstract][Full Text] [Related]
13. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: A SEER database analysis of 162,983 cases. Dasari A; Mehta K; Byers LA; Sorbye H; Yao JC Cancer; 2018 Feb; 124(4):807-815. PubMed ID: 29211313 [TBL] [Abstract][Full Text] [Related]
14. Prognostic factors of metastatic neuroendocrine carcinoma under first-line treatment with platinum etoposide with a focus on NEC score and Rb expression: Results from the multicentre RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network. Hadoux J; Kanaan C; Durand A; Hescot S; Hautefeuille V; Cadiot G; Tauveron I; Laboureau S; Do Cao C; Walter T; Petorin C; Blanchet O; Jannin A; Gu C; Faron M; Leteurtre E; Rousselet MC; Zakeyh JJ; Marchal A; Chatelain D; Beaulaton C; Hervieu V; Ducreux M; Scoazec JY; Baudin E Eur J Cancer; 2021 Jul; 152():100-115. PubMed ID: 34090142 [TBL] [Abstract][Full Text] [Related]